Provided by Tiger Trade Technology Pte. Ltd.

Theravance Biopharma

17.23
+0.45002.68%
Post-market: 17.19-0.0400-0.23%16:20 EDT
Volume:436.19K
Turnover:7.44M
Market Cap:887.22M
PE:8.36
High:17.24
Open:16.97
Low:16.74
Close:16.78
52wk High:21.03
52wk Low:8.33
Shares:51.49M
Float Shares:21.84M
Volume Ratio:1.09
T/O Rate:2.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.06
EPS(LYR):2.06
ROE:44.85%
ROA:-0.54%
PB:2.99
PE(LYR):8.36

Loading ...

Theravance Biopharma Is Maintained at Neutral by B. Riley Securities

Dow Jones
·
Apr 08

B. Riley Raises Price Target on Theravance Biopharma to $17 From $14, Keeps Neutral Rating

MT Newswires Live
·
Apr 07

Theravance Secures Long-Term YUPELRI Patent Litigation Settlement

TIPRANKS
·
Mar 31

Theravance Biopharma Inc -Co's Units and Mylan Enter Settlement Agreement With Mankind on Yupelri Litigation - SEC Filing

THOMSON REUTERS
·
Mar 31

Theravance Biopharma: Theravance & Mylan Granted Mankind License to Market Generic Yupelri in U.S. on or After April 23, 2039

THOMSON REUTERS
·
Mar 31

Theravance Biopharma Inc - Settlement Subject to Review by U.S. Department of Justice and Federal Trade Commission - SEC Filing

THOMSON REUTERS
·
Mar 31

Theravance, Viatris settle Yupelri patent suit, allow Mankind generic launch in 2039

Reuters
·
Mar 31

Theravance Biopharma Is Maintained at Hold by TD Cowen

Dow Jones
·
Mar 23

Theravance Biopharma price target raised to $15 from $13 at TD Cowen

TIPRANKS
·
Mar 23

Theravance Biopharma: Post‑CYPRESS Restructuring Leaves Limited Upside and Justifies Neutral Stance

TIPRANKS
·
Mar 23

Theravance Biopharma Price Target Maintained With a $21.00/Share by BTIG

Dow Jones
·
Mar 20

Theravance Biopharma investors face litigation after 26% stock plunge

Reuters
·
Mar 19

Ireland's Theravance Biopharma Q4 revenue misses expectations

Reuters
·
Mar 19

Theravance Biopharma Q4 Operating Income USD 20.012 Million

Reuters
·
Mar 19

Theravance Biopharma Q4 EPS $1.15 Beats $1.02 Estimate, Sales $45.891M Miss $50.793M Estimate

Benzinga
·
Mar 19

Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10

TIPRANKS
·
Mar 19

Theravance Biopharma Q4 EPS USD 1.15

THOMSON REUTERS
·
Mar 19

Corrected-Theravance Biopharma Q4 Revenue USD 45.9 Million VS. Ibes Estimate USD 58.5 Million (Corrects Amount)

THOMSON REUTERS
·
Mar 19

Theravance Biopharma Q4 Adjusted Net Income USD 3.131 Million VS. Ibes Estimate USD 58.3 Million

THOMSON REUTERS
·
Mar 19

Corrected-Theravance Biopharma Q4 Adjusted Net Income USD 3.131 Million (Removes Reference to Estimate)

THOMSON REUTERS
·
Mar 19